Human NMNAT1 Protein 2383

$300.00 – $1,000.00

Summary

Expression: Baculovirus-Insect Cells
Pure: Yes (SDS-PAGE)
Amino Acid Range: Met1-Thr279

SKU: 2383parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	Q9HAN9
express system	Baculovirus-Insect Cells
product tag	C-His
purity	> 95% as determined by Tris-Bis PAGE
background	Nicotinamide mononucleotide adenylyltransferease (NMNAT), a rate-limiting enzyme present in all organisms, reversibly catalyzes the important step in the biosynthesis of NAD from ATP and NMN. NMNAT also catalyzes the metabolic conversion of potent antitumor prodrugs like tiazofurin and benzamide riboside to their active forms which are analogs of NAD.
molecular weight	The protein has a predicted MW of 33.46 kDa same as Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Human NMNAT1 Protein 2383

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
Nicotinamide mononucleotide adenylyltransferease (NMNAT), a rate-limiting enzyme present in all organisms, reversibly catalyzes the important step in the biosynthesis of NAD from ATP and NMN. NMNAT also catalyzes the metabolic conversion of potent antitumor prodrugs like tiazofurin and benzamide riboside to their active forms which are analogs of NAD.
Protein names Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 (NMN/NaMN adenylyltransferase 1) (EC 2.7.7.1) (EC 2.7.7.18) (Nicotinamide-nucleotide adenylyltransferase 1) (NMN adenylyltransferase 1) (Nicotinate-nucleotide adenylyltransferase 1) (NaMN adenylyltransferase 1)
Gene names NMNAT1,NMNAT1 NMNAT
Protein family Eukaryotic NMN adenylyltransferase family
Mass 9606Da
Function Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Also acts as a cofactor for glutamate and aspartate ADP-ribosylation by directing PARP1 catalytic activity to glutamate and aspartate residues on histones (By similarity). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults (By similarity).
Catalytic activity BINDING 15..17; /ligand="ATP"; /ligand_id="ChEBI:CHEBI:30616"; /evidence="ECO:0000250\|UniProtKB:Q96T66, ECO:0000305\|PubMed:11788603"; BINDING 15; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 15; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 16; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 16; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 17; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 23; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 24; /ligand="ATP"; /ligand_id="ChEBI:CHEBI:30616"; /evidence="ECO:0000250\|UniProtKB:Q96T66"; BINDING 55; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 57; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 57; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 58; /ligand="ATP"; /ligand_id="ChEBI:CHEBI:30616"; /evidence="ECO:0000250\|UniProtKB:Q96T66"; BINDING 92; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 92; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 95; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 95; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 156..158; /ligand="ATP"; /ligand_id="ChEBI:CHEBI:30616"; /evidence="ECO:0000250\|UniProtKB:Q96T66"; BINDING 156; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 158; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 168; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 168; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 169; /ligand="beta-nicotinamide D-ribonucleotide"; /ligand_id="ChEBI:CHEBI:14649"; /evidence="ECO:0000269\|PubMed:11959140, ECO:0007744\|PDB:1GZU"; BINDING 169; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 215; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 219; /ligand="NAD(+)"; /ligand_id="ChEBI:CHEBI:57540"; /evidence="ECO:0000269\|PubMed:11788603, ECO:0007744\|PDB:1KQN"; BINDING 224..227; /ligand="ATP"; /ligand_id="ChEBI:CHEBI:30616"; /evidence="ECO:0000250\|UniProtKB:Q96T66"
Pathway PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from nicotinamide D-ribonucleotide: step 1/1.; PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; deamid
Subellular location Nucleus .
Tissues Widely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain.
Structure Homohexamer (PubMed:11751893). Interacts with ADPRT/PARP1 (PubMed:11248244).
Target Relevance information above includes information from UniProt accession: Q9HAN9
The UniProt Consortium

Human NMNAT1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.